GA-CYBLE
5.4.2021 23:56:07 CEST | Business Wire | Press release
Cyble, a global cyber intelligence firm specializing in providing early warning intelligence on cyber threats, announced today that it has raised a $4M seed financing round led by Blackbird Ventures and Spider Capital, with participation from Xoogler Ventures, Picus Capital, and Cathexis Ventures.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210405005474/en/
The funding comes as Cyble graduates from Y Combinator, which accepted Cyble into its Winter 2021 (W21) cohort and provided pre-seed funding in January of this year. These investments demonstrate the continued trust that investors and clients have in Cyble.
Cyble has made huge progress over the last year. "We started this company with an ambitious goal: to equip organizations with real-time visibility into vulnerabilities in the cyber landscape and help safeguard their businesses. As we continue to deliver what modern organizations need, the seed funding reaffirms our strategy and vision. It will enable Cyble to onboard resources and scale our SaaS platform, Cyble Vision, in lock step with our rapidly growing client base," says Manish Chachada, COO and Co-founder of Cyble.
Michael Neril of Spider Capital noted: “We are excited to partner with Cyble as they scale their revolutionary SaaS platform focused on dark web monitoring. The founding team have deep domain expertise in this space, and we look forward to seeing their product gain further traction in this market.”
Tom Humphrey of Blackbird Ventures noted: "The Cyble team are wild hearts on a mission. We are struck by the progress they have achieved to date and believe they are only just getting started. Dark web monitoring and mitigation capabilities are front of mind for modern organizations and the market is growing rapidly."
Cyble has also signed a partnership with Aditya Birla Group Innovation Fund to jointly identify and engage in the pilot for application and use of Cyble’s offerings at Aditya Birla Group (ABG). Headquartered in India, the Aditya Birla Group is a 150 years old multi-business, multi-national conglomerate. With 45B USD in global revenues, the ABG businesses are leaders in their respective industry spaces. “Developing a system of early warning signals for threats to corporate assets arising from the dark web is a new frontier for our cyber security and is an area of high priority for ABG. We are proud to partner with the Cyble Team to take the lead in testing, refining, adopting and co-innovating new-age cyber security technologies with them,” said Shrenik M Khasgiwala of ABG Innovation Fund.
"We're really excited about what the next 18 to 24 months hold for Cyble," says Beenu Arora, CEO and Co-founder of Cyble. "It's our mission to empower organizations to fortify against increasingly sophisticated cyber threats. We are extremely excited to welcome our new partners and have the additional resources to accelerate our product roadmap and better arm our clients with the tools they require to fight cybercrime."
About Cyble
Cyble
is a global threat intelligence SaaS provider that helps enterprises protect themselves from cybercrimes and exposure in the darkweb. Cyble’s prime focus is to provide organizations with real-time visibility into their digital risk footprint. Backed by Y Combinator as part of the 2021 winter cohort, Cyble has also been recognized by Forbes as one of the top 20 Best Cybersecurity Startups To Watch In 2020. Headquartered in Alpharetta, Georgia, and with offices in Australia, Singapore, and India, Cyble has a global presence. To learn more about Cyble, visit www.cyble.io
. To learn more about Cyble, visit www.cyble.io
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210405005474/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
